Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
by Zacks Equity Research
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
JNJPositive Net Change BMRNPositive Net Change CSTLPositive Net Change NBTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
by Zacks Equity Research
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
GSKPositive Net Change VYGRPositive Net Change ANABPositive Net Change CSTLPositive Net Change
biotechs
Denali Gains 26.6% in a Year: How Should You Play the Stock?
by Zacks Equity Research
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change
biotechnology biotechs pharmaceuticals
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
GSKPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
AZNPositive Net Change CTMXPositive Net Change CSTLPositive Net Change ERASPositive Net Change
biotechs medical pharmaceuticals vaccines
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
GSKPositive Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
BMRNPositive Net Change NVOPositive Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
by Zacks Equity Research
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
AMGNPositive Net Change VYGRPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
by Zacks Equity Research
MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for additional subtypes of pandemic influenza.
MRNAPositive Net Change NVAXPositive Net Change CVACPositive Net Change
biotechs medical messenger-rna vaccines
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
REGNPositive Net Change IONSPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
How to Play Moderna Stock After the Recent Sales Guidance Cut
by Sundeep Ganoria
Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
VYGRPositive Net Change CTMXPositive Net Change STOKPositive Net Change CSTLPositive Net Change
biotechs
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
by Zacks Equity Research
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
BMRNPositive Net Change CTMXPositive Net Change CSTLPositive Net Change IBRXPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
by Zacks Equity Research
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
BMRNPositive Net Change ATRANegative Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
VRTXPositive Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs crispr medical pharmaceuticals
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
by Zacks Equity Research
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
VYGRPositive Net Change CTMXPositive Net Change MIRMPositive Net Change CSTLPositive Net Change
biotechs
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
REGNPositive Net Change GSKPositive Net Change MRNAPositive Net Change SAGENegative Net Change NTLAPositive Net Change
biotechnology biotechs medical pharmaceuticals
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
by Zacks Equity Research
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
BMRNPositive Net Change CTMXPositive Net Change IFRXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACADPositive Net Change VYGRPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
by Zacks Equity Research
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer patients.
JNJPositive Net Change MRKNegative Net Change IBRXPositive Net Change
biotechs medical pharmaceuticals
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Kymera Provides Pipeline Objectives for 2025, Stock Gains
by Zacks Equity Research
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
SNYPositive Net Change BMRNPositive Net Change CSTLPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
by Zacks Equity Research
Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.
ACADPositive Net Change VYGRPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
by Zacks Equity Research
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
BMRNPositive Net Change CTMXPositive Net Change MDGLPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
by Zacks Equity Research
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
TGTXPositive Net Change VYGRPositive Net Change CTMXPositive Net Change CSTLPositive Net Change
biotechs